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• Synchronous gynecological carcinomas from Lynch syndrome are molecularly concordant, suggesting shared origins.
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Available online 30 April 2018Objective. The diagnosis of carcinoma in both the uterus and the ovary simultaneously is not uncommon and
raises the question of synchronous primaries vs. metastatic disease. Targeted sequencing of sporadic synchro-
nous endometrial and ovarian carcinomas has shown that such tumors are clonally related and thus represent
metastatic disease from one site to the other. Our purpose was to investigate whether or not the same applies
to Lynch syndrome (LS), inwhich synchronous cancers of the gynecological tract are twice as frequent as in spo-
radic cases, reflecting inherited defects in DNA mismatch repair (MMR).
Methods. MMR gene mutation carriers with endometrial or ovarian carcinoma or endometrial hyperplasia
were identified from a nationwide registry. Endometrial (n = 35) and ovarian carcinomas (n = 23), including
13 synchronous carcinoma pairs, were collected aswell as endometrial hyperplasias (n=56) and normal endo-
metria (n = 99) from a surveillance program over two decades. All samples were studied for MMR status,
ARID1A and L1CAMprotein expression and tumor suppressor gene promotermethylation, and synchronous car-
cinomas additionally for somatic mutation profiles of 578 cancer-relevant genes.
Results. Synchronous carcinomas were molecularly concordant in all cases. Prior or concurrent complex (but
not simple) endometrial hyperplasias showed a high degree of concordance with endometrial or ovarian carci-
noma as the endpoint lesion.
Conclusions. Our investigation suggests shared origins for synchronous endometrial and ovarian carcinomas
in LS, in analogy to sporadic cases. The similar degrees of concordance between complex hyperplasias and endo-
metrial vs. ovarian carcinoma highlight converging pathways for endometrial and ovarian tumorigenesis overall.artment of Me
oski).
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Endometrial and ovarian carcinomas are among the most common
female cancers in the Western world. In the United States, N60,000
and 20,000 new cases, respectively, are expected to be diagnosed in
2018 [1]. Among gynecologic cancers, endometrial cancer is the mostthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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metrial and ovarian cancer may occur as part of Lynch syndrome (LS),
in which inherited defects in DNAmismatch repair (MMR) underlie au-
tosomal dominantly inherited predisposition to cancers of multiple or-
gans [2]. While colorectal cancer is the most common cancer in LS
overall, the incidence of endometrial cancer equals to or even exceeds
that of colorectal cancer in female carriers of MMR gene mutations
[3,4]. Up to 54% and 24% of female mutation carriers develop endome-
trial and ovarian cancer, respectively, at some point of their lives [3,4].
On the population level, 9% of endometrial cancer cases under
50 years of age [5] and 2% of ovarian cancer cases unselected for age
[6] have been estimated to be due to germline mutations in MMR
genes. Endometrial cancer in LS is of endometrioid histology in ~90%
of cases and associated with earlier age at diagnosis (mean 50 vs.
68 years) and a higher prevalence of lower uterine segment involve-
ment compared to sporadic cases [7,8]. Ovarian cancer in LS is likewise
diagnosed at a younger age (mean45 years,which is 15–20 years earlier
than in sporadic cases), and 77% of epithelial ovarian carcinomas in LS
are non-serous [9] in a marked contrast with the average population
where the high-grade serous type predominates [10].
In 10% of sporadic cases [11] and 20% of LS cases [7,12], carcinomas
are diagnosed in both the uterus and the ovary simultaneously, raising
the question of tumor origins: do the two cancers arise independently
or one as a metastasis of the other? In the sporadic setting, two recent
studies addressed this question by targeted sequencing, and sharedpro-
files of somatic mutations suggested that synchronous tumors repre-
sented metastatic disease from one site to the other [13,14]. However,
synchronous endometrial and ovarian carcinomas from an additional
LS case lacked somatic mutations in common, implying that LS might
constitute an exception to the general rule [14]. Epidemiological obser-
vations suggest that the developmental pathways to endometrial and
ovarian carcinoma may cross far prior to malignant transformation.
Up to 42% of women in whom endometrial sampling reveals atypical
endometrial hyperplasia are found to have simultaneous endometrial
cancer in hysterectomy specimens [15] consistent with the idea that
endometrioid endometrial carcinoma evolves via endometrial hyper-
plasia [16]. Interestingly, some 50% of patients with endometrioid ovar-
ian carcinoma, too, display concurrent atypical endometrial hyperplasia
[17], the significance of which remains to be clarified: does endometrial
hyperplasia represent an early step of synchronous endometrial tumor-
igenesis or have relevance for ovarian cancer development as well,
given that endometrial epithelial cells are considered to be the origins
of endometrioid and clear cell carcinomas of the ovary [18]?
We took advantage of synchronous cancers arising in LS individuals
and consecutive endometrial biopsy specimens from lifelong surveil-
lance of MMR gene mutation carriers to examine the relationship be-
tween endometrial and ovarian tumorigenesis. Our results define the
developmental routes of endometrial and ovarian cancer and are clini-
cally relevant.
2. Materials and methods
2.1. Patients and samples
The nation-wide Hereditary Colorectal Cancer Registry of Finland
was used as a source to identify LS individualswith endometrial or ovar-
ian carcinoma or endometrial hyperplasia. Tumor and preceding sur-
veillance specimens were available from 66 mutation carriers (MLH1
52, MSH2 10, and MSH6 4), including a total number of 213 samples
(Supplementary Table S1). Endometrial hyperplasia specimens were
classified into four categories (simple hyperplasia, SH; simple atypical
hyperplasia, SAH; complex hyperplasia without atypia, CH; and com-
plex hyperplasia with atypia, CAH) in accordance with the WHO1994/
2003 classification, since itwas the original schemaused in sample diag-
nostics [19,20]. A category including SAHwas omitted because only one
SAH sample was identified.A gynecological pathologist had originally determined the histology
of specimens and the diagnosis was verified after sample collection by a
gynecological pathologist (R.B.). Hematoxylin and eosin was used to
stain formalin-fixed paraffin-embedded (FFPE) tissue sections for visual
inspection and tumor sections containing N60% of tumor cells were cho-
sen for DNA extraction performed by a customized protocol [21]. Man-
ual microdissection was used to carefully separate normal, hyperplasia
and tumor samples. The studywas approvedby the Institutional Review
Boards of the Departments of Surgery (466/E6/01) and the Obstetrics
and Gynecology (040/95) of the Helsinki University Central Hospital
(Helsinki, Finland) and Jyväskylä Central Hospital (Jyväskylä, Finland)
(Dnro 5/2007). The National Supervisory Authority for Welfare and
Health (Valvira/Dnro 10741/06.01.03.01/2015) approved the collection
of archival samples.
2.2. Immunohistochemistry (IHC) for L1CAM and ARID1A
PT-Module (Lab Vision, CA, USA) was obtained to perform antigen
retrieval on 4 μmdeparaffinized tissue slides at 98C°/20min in Envision
TMFlex Target Retrieval solution pH9 for L1CAMandpH6.1 for ARID1A
(Agilent Technologies, USA). The antibodies used were Covance SIG-
39110-200 produced in mouse for L1CAM (1:40/20 min, CD171, clone
1E11, Covance) and anti-ARID1A antibody produced in rabbit (1:200/
20 min, HPA005456, polyclonal, Lot D104841, Sigma-Aldrich, USA).
Slides were stained with Autostainer 480 automated immunostainer
(Lab Vision, CA, USA) and hematoxylin (Mayers HTX, Histolab) was
used to counterstain tissue sections. Protein expression was evaluated
and scored from stained slides by twopathologists (R.B. and A.P.).Mem-
branous L1CAM staining of cells was scored as positive/abnormal when
N10%of tumor cells expressed L1CAM. ARID1A expressionwas scored as
negative/abnormal when all tumor cell nuclei stained negative but pos-
itive expression was preserved in stromal cells.
2.3. Mismatch repair (MMR) status
Sample DNA was investigated by polymerase chain reaction (PCR)
using fluorescently labeled mononucleotide repeat markers BAT25
and BAT26. If both markers were stable, the interpretation was micro-
satellite stability (MSS),whereas one or two unstablemarkers indicated
microsatellite-instability (MSI) [22]. Immunohistochemistry (IHC) was
performed to investigate MMR protein expression as described [23].
MMR was regarded deficient by the presence of MSI, absence of MMR
protein, or both.
2.4. Methylation-specific multiplex ligation-dependent probe amplification
(MS-MLPA)
Samples were investigated using methylation-specific (MS)-MLPA
SALSA MLPA ME001-C2 test (MRC-Holland, Amsterdam, The
Netherlands) as described [23] to analyze methylation patterns of 24
general tumor suppressor genes (TSGs) (listed at http://www.mrc-
holland.com) often methylated in several cancers. In addition, custom
designed MS-MLPA probe mix including 7 gene probes supplemented
with Salsa MLPA kit P-300-B1 human DNA reference-2 reagents was
used to analyze methylation alterations in genes often methylated spe-
cifically in endometrial and ovarian cancer as described [24]. The test
produces a methylation dosage ratio (Dm), which varies between 0
and 1.0 and reflects the percentage of methylated DNA. The Dm value
was calculated individually for each sample as previously described
[25]. The Dm value of 0.15 or above was set as the technical threshold
for indication of hypermethylation for all genes included in the 24 TSG
MS-MLPA test [25], except for CDKN2B. The hypermethylation thresh-
olds for each of the seven endometrial and ovarian carcinoma-related
genes included in the custom MS-MLPA test and for CDKN2B included
in the commercial test were determined using LS normal endometrial
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standard deviation.
2.5. Targeted sequencing for somatic mutations
Tumors and corresponding normal DNA samples were sequenced at
the Institute for Molecular Medicine Finland (FIMM; Helsinki, Finland).
Sequencing was performed on Illumina HiSeq 2500 platform (San
Diego, CA) using the Nimblegen Comprehensive Cancer Panel (Roche
Diagnostics), a 4Mb designwith 578 cancer-related genes, as described
[26]. In brief, libraries were prepared using ThruPLEX® DNA-seq Kit,
and the exons captured according to themanufacturer's protocol (Rubi-
con Genomics). The mean target coverage for tumors was 106-fold
(Supplementary Table S2). The variant calling pipeline is described in
Sulonen et al. [27]. VarScan 2 mutation detection algorithm version
2.3.2was used identification of the non-synonymous somaticmutations
from the paired normal and tumor data [28] as described [26]. Variants
with VarScan somatic p-value below 0.01 were selected for subsequent
analyses.
VarSeq (GoldenHelix®) was used to conduct in silico evaluation of
somatic single nucleotide variants. The algorithms used to predict the
effect of amino acid substitution on protein function were SIFT,
PolyPhen-2, MutationTaster, MutationAssessor, FATHMM, and
FATHMMMKL Coding. Mutation ID in COSMIC was provided if the mu-
tation was present in the Catalogue of somatic mutations in cancer
(COSMIC v71, GRCh 37; http://grch37-cancer.sanger.ac.uk/cosmic).
2.6. Statistical analyses
SPSS software version 22.0 (IBM® SPSS® Statistics, Inc. Chicago, IL,
USA) was used for statistical evaluations. Frequency data was analyzed
by Fisher's exact test. Shapiro-Wilk testwas performed to test normality
of data. Comparisons between two groups including numbers of meth-
ylated genes or Dm values were evaluated by the Student's t-test (for
normally distributed samples) or nonparametric Mann-Whitney U test
(for not normally distributed samples). p values b 0.05 (2-tailed) were
considered significant.
3. Results
3.1. Study rationale and frequencies of molecular alterations
Prompted by the discordant preliminary observations between spo-
radic and LS-associated synchronous carcinomas [13,14], we undertook
this study to explore the relationship between endometrial and ovarian
tumorigenesis in LS. Our investigation is based on 213 specimens from
66 carriers of MMR gene mutations and includes carcinomas of the en-
dometrium (endometrioid) and ovary (endometrioid and clear cell), as
well as consecutive specimens of non- and premalignant endometrial
tissues from a surveillance program operative since 1996 [29] (Supple-
mentary Table S1). We recently used this series to investigate the fre-
quencies of MMR, ARID1A, and TSG methylation alterations againstTable 1









MMR-deficient 30/31 (97%) 9/9 (1
Loss of ARID1A expression 14/23 (61%) 9/9 (1
Overexpression of L1CAM 3/22 (14%) 3/7 (4
Average number of methylated endometrial and ovarian cancer
related genes out of total 7
2.3 3.7
Average number of methylated tumor suppressor genes out of
total 24
3.7 3.8
Abbreviations: N/A = not applicable. Proportions are based on cases that could be successfullythe progressive histological abnormality of endometrial specimens
from LS and sporadic cases [30].We now focus on synchronous carcino-
mas (13 pairs from equally many individuals) and endometrial hyper-
plasia – endometrial/ovarian carcinoma combinations (35 pairs from
22 mutation carriers) to explore their clonal relatedness. LS synchro-
nous carcinomas are additionally compared by targeted sequencing.
All LS specimens are investigated for the protein expression of L1CAM,
an adhesion molecule connected to invasion and metastatic potential
[31–33], to supplement our previous set of markers [30] monitoring
early alterations.
Table 1 shows the frequencies of molecular changes detected in the
LS sample series (this study and [30]). Compared to the very high fre-
quencies (up to 100%) for MMR defects and ARID1A expression loss,
LICAM aberrations were less prominent. The highest frequencies were
seen in ovarian clear cell carcinomas (OvCC), of which 43% (3/7)
displayed L1CAMoverexpression. Representative examples of immuno-
histochemical staining results of L1CAM are given in Supplementary
Fig. S1.
3.2. Pairwise evaluation of synchronous gynecological carcinomas for
concordance
Our LS series included 13 pairs of synchronous carcinomas (9 endo-
metrial plus ovarian carcinoma pairs, 3 cases with bilateral ovarian car-
cinomas, and one pair with endometrial and endocervical carcinoma).
Fig. 1 depicts case by case themolecular alterations discovered in the tu-
mors. To systematically compare the paired tumors for concordance,
evaluation criteria were developed taking 5 parameters (MMR status,
ARID1A protein expression, L1CAM protein expression, hypermethyla-
tion status of 7 endometrial and ovarian cancer-related TSGs and hyper-
methylation status of 24 general TSGs) into account (please see footnote
of Fig. 1). A pair was regarded concordant if at least 3 of 5 (or at least
50%) of parameters were concordant. By these criteria, all synchronous
cases were deemed concordant. Synchronous tumors invariably shared
the same MMR and ARID1A expression status, and TSG hypermethyla-
tion patterns also exhibited high intra-pair concordance (Fig. 1). Our
findings thus suggested that the synchronous LS cancers had shared or-
igins (i.e., in each pair, one tumor was likely to be a metastasis of the
other).
To further explore the relationship between those synchronous car-
cinomas that affected different organs (the ovary and the endome-
trium), the 9 synchronous ovarian and endometrial carcinomas were
statistically compared as groups relative to each other and to non-
synchronous ovarian and endometrial carcinomas (Table 2). As molec-
ular parameters, the frequencies of MMR, ARID1A, and L1CAM alter-
ations and the numbers of hypermethylated TSGs (representing two
gene panels), and the methylation dosage ratios (Dm values) for 6
genes most commonly methylated in our series (RSK4, SPARC, HOXA9,
HOXA10, RASSF1 and CDH13) were considered. No significant differ-
ences between the synchronous tumors were found (Fisher's exact
testwas used for frequencies and paired t-test for Dmvalues). Some sig-






















00%) 14/14 (100%) 12/99 (12%) 5/12 (42%) 5/6 (83%) 33/38 (87%)
00%) 12/14 (86%) 0/22 (0%) 0/6 (0%) 1/4 (25%) 6/30 (20%)
3%) 2/13 (15%) N/A 0/4 (0%) 1/4 (25%) 1/28 (4%)
3.2 0.70 1.2 2.3 2.0
3.4 2.4 2.3 3.0 3.8
analyzed.
Table 2
Comparison of synchronous endometrial and ovarian carcinomas with the corresponding
non-synchronous carcinomas from Lynch syndrome patients.
Non-synchronous Synchronous
carcinomas (n = 9)a
Non-synchronous
OvCa (n = 8) OvCa EnCa EnCa (n = 24)
MMR-deficient 100% 100% 100% 97%
ARID1A negative 100% 89% 86% (n =
7)
59% (n = 17)




12% (n = 17)
Average no. of methylation markers
7 EnCa and OvCa
related
3.38 3.44 2.56 2.13
24 TSG 4.00 3.89 5.5 (n =
8)
2.74 (n = 23)
Average Dm
RSK4 0.64 0.71 0.71 0.61
SPARC 0.62 0.71 0.63 0.53
HOXA10 0.48 0.38 0.23 0.23
HOXA9 0.62 0.67 0.54 0.43
RASSF1 0.35 0.33 0.24 (n=
8)
0.28 (n = 23)
CDH13 0.42 0.35 0.25 (n=
8)
0.31 (n = 23)
Abbreviations: Dm, methylation dosage ratio; EnCa, endometrioid endometrial carci-
noma; OvCa, ovarian carcinoma.
a Includes one endocervical/ovarian carcinoma pair. All others are endometrioid en-
dometrial/ovarian carcinoma pairs. If a result was not available from every sample, the ac-
tual number of samples is indicated in parentheses. Bolding indicates that a synchronous
tumor exhibited the closest similarity to its pair rather than nonsynchronous tumors. The
nine synchronous endometrial and ovarian carcinomas were compared relative to each
other and to non-synchronous endometrial and ovarian carcinomas. Significant differ-
ences were detected only between synchronous OvCa and non-synchronous EnCa, as fol-
lows: Number of methylation markers (among 7 endometrial and ovarian cancer related
genes), p=0.042 by t-test; average Dm for RSK4, p=0.036 by t-test; and average Dm for


































































































































































LOC2 MLH1 OvE Yes Yes N/A
LOC2 MLH1 EnCa Yes Yes N/A
LOC3 MLH1 OvCC Yes Yes Yes
LOC3 MLH1 EnCa Yes N/A N/A
LOC4 MLH1 OvE Yes Yes No
LOC4 MLH1 EnCa Yes Yes No
LOC7 MSH2 OvE Yes Yes Yes
LOC7 MSH2 EnCa Yes Yes Yes
LOC8 MSH2 OvCC Yes Yes No
LOC8 MSH2 EnCa Yes Yes Yes
LOC9 MLH1 OvE Yes Yes No
LOC9 MLH1 EnCa Yes Yes No
LOC12 MLH1 OvCC Yes Yes Yes
LOC12 MLH1 CxCa (adeno) Yes N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
LOC16 MLH1 OvE Yes Yes No
LOC16 MLH1 EnCa Yes Yes Yes
LOC18 MLH1 OvE Yes No No
LOC18 MLH1 EnCa Yes No No
OvCa/OvCa
LOC13 MLH1 OvE(1) Yes Yes No
LOC13 MLH1 OvE(2) Yes Yes No
LOC6 MLH1 OvCC Yes Yes Yes
LOC6 MLH1 OvB Yes Yes No
LOC22 MLH1 OvCC(1) Yes Yes N/A
LOC22 MLH1 OvCC(2) Yes Yes N/A
LEC10 MLH1 EnCa Yes Yes No
LEC10 MLH1 CxCa (adeno) Yes Yes No
Shared C
N/AC C C









C C N/A C
C N/A N/A C
C C? N/A C
C C N/A C
C
EnCa-OvCa related
methylaon markers 24 TSG methylaon markers
C C? N/A
C C Shared C
D C N/A C
Fig. 1.Molecular characteristics of synchronous carcinoma pairs from Lynch patients.
95A. Niskakoski et al. / Gynecologic Oncology 150 (2018) 92–98carcinoma comparisons (see footnote for Table 2). Interestingly, L1CAM
was overexpressed in 43% (6/14) of tumors belonging to the 9 synchro-
nous ovarian and endometrial carcinoma pairs, compared to 12% (3/25)
of non-synchronous ovarian and endometrial carcinomas (p = 0.047).
The latter observation further supports the interpretation of metastatic
disease, since L1CAM is known to promote motility and invasion [31].
3.3. Targeted sequencing of synchronous carcinomas for somatic mutations
Sufficient DNAwas available from 5 cases for targeted sequencing of
578 cancer-relevant genes as an additional means to assess clonal relat-
edness (Fig. 1, Table 3, Supplementary Table S3). Somaticmutation pro-
files indicated unequivocally shared origins for the paired tumors from
three cases (LOC3, LOC18, and LOC13) and a tentatively shared origin
for a fourth one (LOC16). The question of shared vs. independent origins
remained unresolved in case LOC6with ovarian clear cell carcinoma and
ovarian borderline tumor sharing a single nonsynonymous low-
frequency mutation (in CTNNB1) predicted to be damaging (Table 3,
Supplementary Table S3).
3.4. Comparison of endometrial hyperplasias and paired carcinomas for
concordance
Molecular characteristics of endometrial hyperplasias preceding or
coinciding with endometrial carcinoma are shown case by case in
Fig. 2. Analogous data with ovarian carcinoma as the endpoint lesion
are displayed in Fig. 3. Molecular alterations in endometrial hyperpla-
sias were compared to those in the paired carcinomas and concor-
dance/discordance assigned by the same criteria as for the carcinoma-
carcinoma comparisons above (Fig. 1). SH revealed a discordant pattern
with synchronous or metachronous endometrial or ovarian carcinoma
in all cases that could be evaluated (2/2, 100%, Figs. 2 and 3), arguing
against premalignant potential of SH. CH and CAH were concordant
with endometrial carcinoma as the endpoint lesion in 15 of 19 cases
(79%) (CH 2/2 and CAH 13/17, Figs. 2 and 3), implying a cancer precur-
sor role for complex hyperplasias without or with atypia. Interestingly,
the proportion of concordant cases was comparable with ovarian carci-
noma as the endpoint (9/11, 82%) (CH 0/1 and CAH 9/10, Fig. 3), sug-
gesting that a developmental route from endometrial hyperplasia toovarian carcinoma might also be possible. Cases LOC1 and LOC13 pro-
vide illustrative examples of a high molecular similarity of prior or con-
current CAH with ovarian carcinoma from the same cases. This
observation together with the common origins of synchronous endo-
metrial and ovarian carcinomas in LS as discussed above imply that
Table 3
Summary of somatic mutations shared by synchronous Lynch carcinomas, based on deep sequencing of 578 cancer-relevant genes.
No. of somatic mutations, VarScan p b 0.01
Case ID Tumor 1 Tumor 2 Shared Shared (relaxed criteria)a Examples of shared somatic mutations predicted damagingb
LOC3 2915 (OvCC) 72 (EnCa) 2 N/A TGFBR2 fs, JAK1 fs
LOC16 23 (OvE) 132 (EnCa) 0 4 ARID2 R1679Q, MAP2K2 E328K, SMARCB1 R350W
LOC18 38 (OvE) 1544 (EnCa) 10 N/A PTEN K332*, PTEN fs
LOC13 65 (OvE) 78 (OvE) 41 N/A PIK3CA R88Q, PTEN fs, ARID1A fs (two different)
LOC6 37 (OvCC) 41 (OvEB) 0 1 CTNNB1 R565H
Abbreviations: fs, frameshift; N/A, not applicable.
a Somatic VarScan p b 0.05 in both tumors (indicated for cases without any shared mutations with p b 0.01).
b A complete list of mutations is given in Supplementary Table S3.
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morigenesis may be higher than appreciated before.
4. Discussion
The epidemiology of endometrial and ovarian cancer is intertwined,
and several possible mechanisms, including hormonal and inflamma-
tion and immune system-related, may underlie this phenomenon [34].
LS provides an efficient tool to investigate the pathogenesis of endome-
trial and ovarian carcinoma for the following reasons: (i) the lifetime
risks of these cancers are significantly elevated in LS compared to the
average population [3,4], (ii) multiple lesions (both malignant and be-
nign) in the same individuals are common [7,12], and (iii) lifelong sur-
veillance against gynecological cancer results in consecutive specimens
that are invaluable for research [35].
In LS, the clinically important issue of independent primary tumors
vs. metastatic disease in the case of synchronous endometrial and ovar-
ian cancers is unsettled, so far. We evaluated 13 synchronous carcino-






























































































LEC1 MLH1 CH -2 Yes No No D
LEC1 MLH1 CAH 0 (No) No No ND
LEC1 MLH1 EnCa 0 Yes Yes No
LEC6 MLH1 SH -1 No N/A N/A D
LEC6 MLH1 EnCaCC 0 Yes Yes Yes
LEC8 MLH1 CAH -1 Yes No No D
LEC8 MLH1 CAH 0 Yes No No ND
LEC8 MLH1 EnCa 0 Yes N/A N/A
LEC9 MLH1 CAH -3 Yes Yes N/A ND
LEC9 MLH1 EnCa 0 Yes Yes No
LEC11 MLH1 SH 0 Yes No N/A D N/A N/A N/A N/A N/A
LEC11 MLH1 CAH 0 Yes N/A N/A ND N/A N/A N/A N/A N/A
LEC11 MLH1 EnCa 0 Yes N/A No
LEC12 MLH1 CAH 0 Yes N/A No ND
LEC12 MLH1 EnCa 0 Yes N/A N/A
LEC13 MSH2 CH 0 Yes N/A N/A D
LEC13 MSH2 EnCa 0 Yes No No
LEC14 MLH1 CAH 0 (No) Yes N/A ND
LEC14 MLH1 EnCa 0 (No) Yes N/A
LEC15 MLH1 CH 0 Yes Yes Yes D
LEC15 MLH1 CAH 0 Yes Yes N/A C?
LEC15 MLH1 EnCaCC 0 Yes Yes Yes
LEC16 MLH1 CAH 0 Yes N/A No C?
LEC16 MLH1 EnCa 0 Yes No No
LEC17 MLH1 CAH -3 Yes N/A N/A ND
LEC17 MLH1 CAH 0 Yes No No ND
LEC17 MLH1 EnCa 0 Yes No No
LEC21 MLH1 SH -2 Yes N/A N/A D N/A N/A N/A N/A N/A
LEC21 MLH1 CAH 0 Yes No N/A C?
LEC21 MLH1 EnCa 0 Yes Yes No
LEC22 MSH2 CAH 0 Yes No No C
LEC22 MSH2 EnCa 0 Yes N/A No
LEC25 MSH6 CAH 0 (No) No No C?
LEC25 MSH6 EnCa 0 Yes No N/A
Endometrial and ovarian cancer related 
methylaon markers
Fig. 2.Molecular characteristics of endometrial hyperplasias occurring prior to obilateral ovarian carcinomas, and one pair with endometrial and
endocervical carcinoma) (Fig. 1) and our results indicate shared origins.
Frequent L1CAMoverexpression among the synchronous tumorswas in
agreement with the interpretation of metastatic disease. The available
data are thus consistent with metastatic disease in synchronous cases
from sporadic [14] and LS cases (this study); however, the direction of
metastasis is unknown. Kelemen et al. [11] explored the patterns ofmo-
lecular alterations (PTEN and MMR protein expression) in three groups
of sporadic tumors: ovarian carcinomas synchronous with endometrial
carcinoma, non-synchronous endometrial carcinomas, and non-
synchronous ovarian carcinomas. They found that ovarian carcinomas
synchronous with endometrial carcinoma showed a greater similarity
relative to non-synchronous endometrial carcinoma than non-
synchronous endometrioid ovarian carcinoma, possibly suggesting a
metastatic spread from the endometrium to the ovary. In our LS series,
synchronous ovarian carcinoma (or endometrial carcinoma) showed
the closest molecular similarity to its synchronous pair, and a closer
similarity to non-synchronous cancer of the same rather than the differ-












































































N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A ND













24 tumor suppressor gene methylaon markers





































































































































































































































































LOC1 MLH1 CAH -3 Yes No No D C C
LOC1 MLH1 CH 0 (No) No No N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A D N/A D
LOC1 MLH1 OvE 0 Yes Yes No
LOC5 MSH2 CAH 0 Yes N/A No ND C C
LOC5 MSH2 OvE 0 Yes Yes Yes
LOC9 MLH1 CAH 0 Yes No No C C C C C C
LOC9 MLH1 OvE 0 Yes Yes No
LOC9 MLH1 EnCa 0 Yes Yes No
LOC13 MLH1 CAH 0 Yes No No C C C C C C
LOC13 MLH1 OvE(1) 0 Yes Yes No
LOC13 MLH1 OvE(2) 0 Yes Yes No
LOC16 MLH1 CAH 0 Yes No No ND C C D C D
LOC16 MLH1 OvE 0 Yes Yes No
LOC16 MLH1 EnCa 0 Yes Yes Yes
LOC18 MLH1 CAH 0 Yes No No C C? C C C C
LOC18 MLH1 OvE 0 Yes No No
LOC18 MLH1 EnCa 0 Yes No No
LOC21 MLH1 SH 0 No N/A No D C? D?
LOC21 MLH1 OvCC 0 Yes Yes No
LOC22 MLH1 CAH -9 Yes No No C? D D? C D ND
LOC22 MLH1 CAH -7 Yes N/A N/A C? D C C? D C
LOC22 MLH1 OvCC(1) 0 Yes Yes N/A
LOC22 MLH1 OvCC(2) 0 Yes Yes N/A
EnCa and OvCa related
methylaon markers
24 TSG methylaon markers Relave to OvCa (1) Relave to OvCa (2) Relave to EnCa
Fig. 3.Molecular characteristics of endometrial hyperplasias occurring prior to or concurrently with ovarian carcinoma (and synchronous endometrial carcinoma) from Lynch syndrome
patients.
97A. Niskakoski et al. / Gynecologic Oncology 150 (2018) 92–98pair may suggest that metastasis occurs soon after the first tumor has
arisen. No conclusions about the direction of metastasis can be drawn.
In the sporadic setting, L1CAM overexpression has been found to be
an adverse prognostic sign [31]. Among stage I endometrioid endome-
trial cancers, which are usually associated with excellent prognosis,
L1CAM overexpression identifies a subgroup with significantly poorer
disease-free and overall survival [32]. Among ovarian carcinomas,
L1CAM overexpression signals poor outcome of endometrioid, but not
clear cell type [33]. In ovarian and endometrial carcinomas from our
LS patients, L1CAM overexpression was significantly more common in
synchronous (43%) than non-synchronous cases (12%). Patients with
synchronous carcinomas exhibited excellent survival (the crude 10-
year survival was 83%) with no apparent association with L1CAM ex-
pression (data not shown). Synchronous endometrial and ovarian carci-
nomas from sporadic cases, too, are associated with indolent course,
which is unexpected of a metastatic disease. An isolated metastatic dis-
ease distinct from the usual progressive metastatic disease was pro-
posed as a possible explanation [13,14].
The accumulating evidence suggests that endometrioid and clear
cell ovarian carcinomas arise from endometrial epithelial cells via atyp-
ical endometriosis and borderline tumors [36]. It remains to be resolved
if mutations in endometriosis are critical or alternatively, if mutations in
eutopic endometriummight first cause predisposition to endometriosis
that subsequently develops intomalignancy [18]. Our study reveals that
endometrial hyperplasias show a comparable degree of concordance
relative to endometrial carcinomavs. ovarian carcinoma as the endpoint
lesions (Figs. 2 and 3). Based on ourfindings, a possible role for endome-
trial hyperplasias in ovarian tumorigenesis cannot be excluded and ad-
ditional research is warranted. In line with this notion, our Lynch series
includes two cases with CAH treated with hysterectomy without pro-
phylactic salpingo-oophorectomy and both developed ovarian carci-
noma (LOC1 was diagnosed with OvE 3 years later and LOC22 with
bilateral OvCC 7 years later; Fig. 3).
Compared to many existing studies, the longitudinal sample cohort
from over two decades of gynecological surveillance is a major advan-
tage of our investigation. The availability of synchronous and non-
synchronous endometrial and ovarian carcinomas, as well as consecu-
tive endometrial specimens preceding the malignant stage, formed an
excellent basis to dissect the relationship between endometrial and
ovarian tumorigenesis. The inclusion of both genetic and epigenetic
markers in molecular evaluations can also be considered as a strength.
On the other hand, our investigation has some important limitations.
The amount and/or quality of archival tissue specimens was sometimes
suboptimal for a successful completion of all intended analyses. More-
over, our deep sequencing experiments relied on a gene panel instead
of whole exomes; nevertheless, the complete coding regions of 578
established cancer driver genes (e.g., ARID1A, PTEN, and PIK3CA relevantfor endometrioid endometrial and non-serous ovarian carcinomas)
were covered.
In conclusion, our genetic and epigenetic analyses indicate shared
origins for synchronous endometrial and ovarian carcinomas in LS.
Moreover, endometrial hyperplasias detected in a long-term surveil-
lance program exhibit close molecular similarity to endometrial carci-
nomas and likewise ovarian carcinomas as the endpoint lesions,
suggesting early convergence of endometrial and ovarian tumorigene-
sis. In MMR genemutation carriers, surveillance for endometrial cancer
by gynecological examination, transvaginal ultrasound and aspiration
biopsy is recommended starting from age 35–40 years with the primary
aim to detect premalignant lesions (endometrial hyperplasia) or early-
stage endometrial carcinoma [35,37]. Furthermore, prophylactic hyster-
ectomy and bilateral oophorectomy which prevent the development of
endometrial and ovarian cancer, is recommended for mutation carriers
who have completed their families [35,37]. The multilevel ties we ob-
served between endometrial and ovarian tumorigenesis emphasize
that whenever an endometrial lesion (CH, CAH, or endometrial cancer)
is detected, the possibility of ovarian involvement should be kept in
mind and vice versa.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ygyno.2018.04.566.Acknowledgments
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